Dihydroberberine
CAS No. 483-15-8
Dihydroberberine ( —— )
Catalog No. M21509 CAS No. 483-15-8
Dihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 87 | In Stock |
|
10MG | 155 | In Stock |
|
25MG | 290 | In Stock |
|
50MG | 430 | In Stock |
|
100MG | 619 | In Stock |
|
200MG | Get Quote | In Stock |
|
500MG | Get Quote | In Stock |
|
1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDihydroberberine
-
NoteResearch use only not for human use.
-
Brief DescriptionDihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.
-
DescriptionDihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorhERG; HSP90
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number483-15-8
-
Formula Weight337.4
-
Molecular FormulaC20H19NO4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc(ccc1c2CN(CCc(c3c4)cc5c4OCO5)C3=C1)c2OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yu D et al. Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells. PLoS One. 2017 Aug 1;12(8):e0181823.
molnova catalog
related products
-
O-Nornuciferine
O-Nornuciferine reveals distinct in vitro hERG blockages measured in HEK293 cells with the IC50 value of 2.89 uM.
-
Daphnetin
Daphnetin, a natural coumarin derivative, is a protein kinase inhibitor, inhibits EGFR, PKA and PKC with IC50 of 7.67 μM, 9.33 μM and 25.01 μM, respectively, also known to exhibit anti-inflammatory and anti-oxidant activities.
-
(Rac)-JBJ-04-125-02
JBJ-04-125-02 is effective as a single agent in both in vitro and in vivo models of EGFR-mutant lung cancer.